TheraSense Continuous Glucose Monitor R&D To Get Boost From IPO
This article was originally published in The Gray Sheet
Executive Summary
Ongoing development of TheraSense's continuous glucose monitoring system will be funded in part through a planned initial public offering of up to $115 mil. in common stock.
You may also be interested in...
Cygnus GlucoWatch Pilot Marketing Program To Begin In April
Cygnus plans to kick off a pilot marketing program in April targeting 100-150 Type 1 diabetes patients to gauge firsthand consumer experience with the GlucoWatch Biographer. The non-invasive glucose monitoring system was approved by FDA on March 22.
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.